X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1606) 1606
Publication (99) 99
Book Review (10) 10
Book Chapter (9) 9
Book / eBook (4) 4
Dissertation (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (1015) 1015
humans (997) 997
female (752) 752
chemotherapy (736) 736
middle aged (727) 727
aged (705) 705
index medicus (687) 687
male (677) 677
adult (561) 561
antineoplastic combined chemotherapy protocols - therapeutic use (526) 526
second-line chemotherapy (480) 480
cancer (467) 467
treatment outcome (407) 407
docetaxel (367) 367
lung neoplasms - drug therapy (319) 319
cisplatin (289) 289
trial (249) 249
second-line (246) 246
carcinoma, non-small-cell lung - drug therapy (242) 242
gemcitabine (236) 236
care and treatment (234) 234
second-line therapy (230) 230
aged, 80 and over (228) 228
disease-free survival (222) 222
antineoplastic combined chemotherapy protocols - adverse effects (220) 220
second-line treatment (216) 216
therapy (215) 215
medicine & public health (210) 210
paclitaxel (210) 210
irinotecan (208) 208
antineoplastic agents - therapeutic use (205) 205
survival (197) 197
survival rate (190) 190
retrospective studies (179) 179
pharmacology & pharmacy (176) 176
combination (168) 168
second line (165) 165
deoxycytidine - analogs & derivatives (161) 161
neoplasm staging (161) 161
lung neoplasms - pathology (159) 159
metastasis (158) 158
survival analysis (158) 158
oxaliplatin (154) 154
drug administration schedule (153) 153
phase-iii trial (153) 153
phase-ii trial (152) 152
carcinoma (149) 149
prognosis (149) 149
disease progression (148) 148
supportive care (148) 148
non-small cell lung cancer (140) 140
camptothecin - analogs & derivatives (135) 135
research (134) 134
drug resistance, neoplasm (133) 133
respiratory system (132) 132
hematology, oncology and palliative medicine (131) 131
phase-ii (130) 130
neoplasm metastasis (129) 129
salvage therapy (127) 127
neoplasm recurrence, local - drug therapy (126) 126
carcinoma, non-small-cell lung - pathology (123) 123
deoxycytidine - administration & dosage (122) 122
drug therapy (122) 122
paclitaxel - administration & dosage (120) 120
clinical trials (119) 119
5-fluorouracil (116) 116
bevacizumab (115) 115
adenocarcinoma - drug therapy (114) 114
carboplatin (114) 114
fluorouracil (114) 114
open-label (114) 114
analysis (113) 113
cancer research (113) 113
antineoplastic agents (111) 111
lung neoplasms - mortality (111) 111
taxoids - administration & dosage (111) 111
camptothecin - administration & dosage (110) 110
lung cancer, non-small cell (109) 109
cisplatin - administration & dosage (108) 108
antimitotic agents (107) 107
antineoplastic combined chemotherapy protocols - administration & dosage (105) 105
fluorouracil - administration & dosage (104) 104
stomach neoplasms - drug therapy (101) 101
pemetrexed (100) 100
erlotinib (98) 98
vinorelbine (95) 95
carcinoma, non-small-cell lung - mortality (93) 93
lung cancer (91) 91
randomized-trial (91) 91
adenocarcinoma (90) 90
kaplan-meier estimate (90) 90
gastric cancer (89) 89
multicenter (88) 88
antineoplastic agents - administration & dosage (84) 84
colorectal cancer (83) 83
2nd-line treatment (81) 81
leucovorin (81) 81
pancreatic cancer (81) 81
doxorubicin (80) 80
follow-up studies (79) 79
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1491) 1491
German (47) 47
French (28) 28
Japanese (20) 20
Russian (16) 16
Korean (10) 10
Chinese (7) 7
Polish (6) 6
Portuguese (4) 4
Italian (3) 3
Spanish (3) 3
Czech (2) 2
Hungarian (2) 2
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CANCER, ISSN 0008-543X, 04/2011, Volume 117, Issue 7, pp. 1422 - 1428
Journal Article
Cancer, ISSN 0008-543X, 10/2011, Volume 117, Issue 20, pp. 4617 - 4622
BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin... 
second‐line and temozolomide | chemotherapy | neuroendocrine cancer | PDEC | second-line and temozolomide | TRACT | PHASE-II TRIAL | ETOPOSIDE | NEUROENDOCRINE TUMORS | CISPLATIN | ONCOLOGY | SMALL-CELL CARCINOMA | Capecitabine | Humans | Middle Aged | DNA Repair Enzymes - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | DNA Repair - genetics | Promoter Regions, Genetic - genetics | Bevacizumab | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Carcinoma, Neuroendocrine - chemistry | Retrospective Studies | Dacarbazine - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Neuroendocrine - genetics | Etoposide - administration & dosage | Treatment Outcome | DNA Methylation - genetics | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Aged | Deoxycytidine - analogs & derivatives | Salvage Therapy - methods | Endocrine gland cancer | Care and treatment | Dosage and administration | Temozolomide | Research | Carcinoma | Medical treatment | Medical services | Etoposide | Patients | Survival | Cisplatin | Metastases | Chemotherapy | Methylation | Cancer | temozolomide | second-line | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 15, pp. 2306 - 2314
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 08/2014, Volume 9, Issue 8, pp. 1180 - 1186
Over the past decade, well tolerated second-line therapies for advanced non–small-cell lung cancer have been approved including erlotinib and pemetrexed in... 
Second line | Non–small-cell lung cancer | Erlotinib | Pemetrexed | Docetaxel | Predictors | Non-small-cell lung cancer | GEFITINIB | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | PLUS CARBOPLATIN | MAINTENANCE THERAPY | PHASE-III TRIAL | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Age Factors | Guanine - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Retrospective Studies | Drug Therapy - trends | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate - trends | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - ethnology | British Columbia | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Asian Continental Ancestry Group - statistics & numerical data | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage
Journal Article
Cancer, ISSN 0008-543X, 08/2007, Volume 110, Issue 3, pp. 556 - 563
Journal Article
Cancer, ISSN 0008-543X, 04/2011, Volume 117, Issue 7, pp. 1422 - 1428
BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced... 
advanced small bowel adenocarcinoma | chemotherapy | second line | survival | FOLFIRI
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2014, Volume 25, Issue 12, pp. 2328 - 2338
Journal Article
Cancer, ISSN 0008-543X, 09/2015, Volume 121, Issue 18, pp. 3290 - 3297
Journal Article
Medicine (United States), ISSN 0025-7974, 05/2017, Volume 96, Issue 19, p. e6769
Background: This study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity, and efficacy of second-line chemotherapy with FOLFIRINOX... 
FOLFIRINOX | pancreatic cancer | gemcitabine | second-line chemotherapy | phase I/II study | LEUCOVORIN | EFFICACY | ADENOCARCINOMA | OXALIPLATIN | FOLINIC ACID | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | RANDOMIZED PHASE-II | IRINOTECAN | PACLITAXEL PLUS GEMCITABINE | JAPANESE PATIENTS | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Pancreatic Neoplasms - pathology | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Treatment outcome | Cancer patients | Care and treatment | Chemotherapy | Usage | Pancreatic cancer | Analysis | Diagnosis | Cancer
Journal Article
Cancer, ISSN 0008-543X, 12/2019, Volume 125, Issue 24, pp. 4426 - 4434
Background Although gemcitabine plus platinum chemotherapy is the established first‐line regimen for advanced biliary cancer (ABC), there is no standard... 
gallbladder cancer | bile duct cancer | biliary cancer | chemotherapy | cholangiocarcinoma | second line
Journal Article
Endocrine-Related Cancer, ISSN 1351-0088, 06/2015, Volume 22, Issue 3, pp. 289 - 298
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 8, pp. 1475 - 1484
Journal Article
Japanese journal of clinical oncology, ISSN 0368-2811, 2015, Volume 45, Issue 7, pp. 670 - 676
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2013, Volume 24, Issue 11, pp. 2850 - 2854
Journal Article